#CEACAM5 - Twitter Hashtag

17 days ago

LigaChem Bio plans to begin clinical trials of the world’s first bispecific ADC targeting both CD20 and CD22. #ADC #Pfizer #LigaChemBiosciences #CD20 #CD22 #AstraZeneca #Enhertu #bispecificADC #CEACAM5 #Besponsa #Sanofi #DaiichiSankyo #ResearchandMarkets https://t.co/ZINKZhXoYH

0

2

1

0

120

Biosensors @Biosensors_MDPI

7 months ago

📣Call for Reading: #Communication A Multimode Microfiber Specklegram Biosensor for Measurement of CEACAM5 through AI Diagnosis by Yuhui Liu, et al. https://t.co/xZpz0U8CWH #multimode #microfiber #specklegram #CEACAM5 #AI #biosensors #mdpi #openaccess

Biosensors_MDPI's tweet photo. 📣Call for Reading:

#Communication
A Multimode Microfiber Specklegram Biosensor for Measurement of CEACAM5 through AI Diagnosis

by Yuhui Liu, et al.

https://t.co/xZpz0U8CWH

#multimode #microfiber #specklegram #CEACAM5 #AI
#biosensors #mdpi #openaccess https://t.co/AmwhSnt0y9

0

2

0

57

Martin Dietrich, MD, PhD

@DoctorDietrich

over 2 years ago

Excited to be introducing this new biomarker hopeful at IASLC North America! Please join us for this update presentation in Chicago. #nsclc #lcsm #ceacam5

PER @gotoPER

over 2 years ago

Don’t miss the program chair, Martin F. Dietrich, MD, PhD, & expert speakers, David Planchard, MD, PhD & Ming Tsao, FRCPC, MD, at our satellite symposium on CEACAM5. Register now: https://t.co/ye6fd43958 #gotoPER #NACLC23 #lcsm @DoctorDietrich @dplanchard

gotoPER's tweet photo. Don’t miss the program chair, Martin F. Dietrich, MD, PhD, & expert speakers, David Planchard, MD, PhD & Ming Tsao, FRCPC, MD, at our satellite symposium on CEACAM5. Register now: https://t.co/ye6fd43958 #gotoPER #NACLC23 #lcsm @DoctorDietrich @dplanchard https://t.co/Uev6RgQ8ML

0

4

2

0

2K

0

5

1

0

1K

Stephen V Liu, MD

@StephenVLiu

over 2 years ago

#DCLung23 Great overview of antibody drug conjugates by Dr. @KatherineScilla. ADCs targeting #HER3 and #Trop2 being explored without predictive biomarkers; #CEACAM5 and #MET exploring activity in IHC+ cases. Great potential, waiting for more data.

StephenVLiu's tweet photo. #DCLung23 Great overview of antibody drug conjugates by Dr. @KatherineScilla. ADCs targeting #HER3 and #Trop2 being explored without predictive biomarkers; #CEACAM5 and #MET exploring activity in IHC+ cases. Great potential, waiting for more data. https://t.co/VlwgLbRlnj

0

19

9

5

2K

CancerNetwork®

@CancerNetwrk

almost 3 years ago

Join PER at our Satellite Symposium on CEACAM5 at the 35th European Congress of Pathology! Tune in Live or experience in person at the Convention Centre Dublin in Ireland! Registration now open: https://t.co/zWMu0dXly2 #gotoPER #CEACAM5 #CME

CancerNetwrk's tweet photo. Join PER at our Satellite Symposium on CEACAM5 at the 35th European Congress of Pathology! Tune in Live or experience in person at the Convention Centre Dublin in Ireland! Registration now open: https://t.co/zWMu0dXly2 #gotoPER #CEACAM5 #CME https://t.co/PKQuFVTWIT

0

2

0

1

477

Stephen V Liu, MD

@StephenVLiu

almost 3 years ago

What do we know about expression of CEACAM5, the target of the antibody drug conjugate (ADC), tusamitamab ravtansine, in NSCLC? Report @LungCaJournal shows high #CEACAM5 expression in 25% of NSCLC, higher in #KRAS+ NSCLC (35%) and in PDL1 neg/low vs high. https://t.co/K3nDelcXFJ

0

46

20

6

10K

MOASC

@MOASC_Office

almost 3 years ago

Join us on July 11th at 5:30pmfor a 60-minute educational webinar covering the role #Biomarkers play in #NSCLC including #CEACAM5 with @HatimHusainMD from @UCSDCancer_COE Register at https://t.co/s3LxFTUeaB

MOASC_Office's tweet photo. Join us on July 11th at 5:30pmfor a 60-minute educational webinar covering the role #Biomarkers play in #NSCLC including #CEACAM5 with @HatimHusainMD from @UCSDCancer_COE Register at https://t.co/s3LxFTUeaB https://t.co/GCZ6jIfNhj

0

2

0

230

Stephen V Liu, MD

@StephenVLiu

about 3 years ago

Dr. @Joshua_Reuss gives a great talk at #TexasLung23 on antibody drug conjugates including ADCs targeting #Trop2 #HER2 #HER3 #B7H7 #CEACAM5. Important class of agents, each with a unique target and set of toxicities. How will we use these in the future: combinations? 1L?

StephenVLiu's tweet photo. Dr. @Joshua_Reuss gives a great talk at #TexasLung23 on antibody drug conjugates including ADCs targeting #Trop2 #HER2 #HER3 #B7H7 #CEACAM5. Important class of agents, each with a unique target and set of toxicities. How will we use these in the future: combinations? 1L? https://t.co/Opb222LeGm

0

22

4

3

2K

@onc_ce

over 3 years ago

19b) Findings support #CEACAM5 as a potential therapeutic target and clinical development of #ADCs 🫁 CEACAM5 is preferentially expressed in #NSQ #NSCLC rather than in SQ NSCLC 🫁 #Tusamitamab_ravtansine is the first CEACAM5 emaytansinoid ADC to be evaluated in human subjects

onc_ce's tweet photo. 19b) Findings support #CEACAM5 as a potential therapeutic target and clinical development of #ADCs
🫁 CEACAM5 is preferentially expressed in #NSQ #NSCLC rather than in SQ NSCLC
🫁 #Tusamitamab_ravtansine is the first CEACAM5 emaytansinoid ADC to be evaluated in human subjects https://t.co/iFNXftq6oS

1

2

0

1

1K

@onc_ce

over 3 years ago

19a) We mentioned Anti-#CEACAM5 therapy above . . . CEACAM5 is a #glycoprotein implicated in a variety of oncogenic activities, and was first recognized as a marker for #coloncancer.

onc_ce's tweet photo. 19a) We mentioned Anti-#CEACAM5 therapy above . . . CEACAM5 is a #glycoprotein implicated in a variety of oncogenic activities, and was first recognized as a marker for #coloncancer. https://t.co/sWwr6Th5MW

1

4

0

2K

Fawzi Abu Rous, MD

@FawziAbuRous

over 3 years ago

🚨🫁Great #tweetorial by @NarjustFlorezMD & @ShrutiPatelMD on #CEACAM5 🎯 #ADC A few things to 🤔 ➡️#NSQ express more #CEACAM5 than #SQ: ⬆️ #Tusa activity ➡️Role of combos to ⬆️ activity in #SQ ➡️Activity in #CEACAM5 ⬇️ & intmdte ➡️Role of #CEA as a serum marker #lcsm #OncTwitter

@onc_ce

over 3 years ago

1a) Welcome to our #accredited #tweetorial on The Role of #CEACAM5-Targeted Therapeutics in Patients with CEA-Positive #NSCLC. #LCSM @MedTweetorials

1

9

8

1

5K

1

6

3

0

3K

@onc_ce

over 3 years ago

23b) 🫁 ~20% of patients with #NSCLC #adenocarcinoma have an overexpression of #CEACAM5, and CEACAM5 is NOT found in normal lung tissue 🫁 #Tusamitamab_ravtansine is a 🥇in class #CEACAM5-targeted #ADC currently undergoing clinical trials.

1

2

0

258

@onc_ce

over 3 years ago

23a) To 🎁 up, 🔑points: 🫁 36% of patients with #NSCLC do NOT have a driver mutation that is targetable by an @US_FDA approved drug 🫁 A novel target, carcinoembryonic antigen–related cell adhesion molecule 5 (#CEACAM5) known to us from #coloncancer, may hold promise

1

4

0

214

@onc_ce

over 3 years ago

22) #CEACAM5 is preferentially expressed in #NSQ_NSCLC rather than in SQ NSCLC. The phase II trial of #tusamitamab_ravtansine showed promising antitumor activity in heavily pretreated advanced NSQ NSCLS with CAECAM5 expression >= 50% of tumor cells. ORR: 20.3%, mDoR: 5.6mo.

onc_ce's tweet photo. 22) #CEACAM5 is preferentially expressed in #NSQ_NSCLC rather than in SQ NSCLC. The phase II trial of #tusamitamab_ravtansine showed promising antitumor activity in heavily pretreated advanced NSQ NSCLS with CAECAM5 expression >= 50% of tumor cells. ORR: 20.3%, mDoR: 5.6mo. https://t.co/KN4UcgAU2q

1

2

0

1

305

@onc_ce

over 3 years ago

20) The big challenge ⚠️ that we have with enrollment, especially in the frontline setting but in all settings as well, is that patients need to have a ➕ #CEACAM5 test to enroll.

1

3

0

138

@onc_ce

over 3 years ago

18) 🏥Phase 2 #CARMEN_LC05 trial https://t.co/Pwt4qSCPBo 💉Comparing #tusamitamab_ravtansine + #pembro vs pembro alone 🦠metastatic #nonsquamous #NSCLC 🔬 >50% of tumor expresses #CEACAM5 at 2+ intensity

1

2

0

203

@onc_ce

over 3 years ago

17) 🏥#CARMEN_LC04 trial https://t.co/WFDmfLuzeo 💪🏽Single arm 💉#tusamitamab_ravtansine with #ramucirumab 🦠metastatic #nonsquamous #NSCLC 🔬 >50% of tumor expresses #CEACAM5 at 2+ intensity 🦀disease has progressed after platinum+IO

1

3

0

227

@onc_ce

over 3 years ago

16) 🏥Phase 3 #CARMEN_LC03 trial https://t.co/Qf8QQJaImb 💉Comparing #tusamitamab ravtansine vs #docetaxel 🦠metastatic nonsquamous #NSCLC 🔬 >50% of tumor expresses #CEACAM5 at 2+ intensity 🦀disease has progressed after prior therapy

onc_ce's tweet photo. 16)
🏥Phase 3 #CARMEN_LC03 trial https://t.co/Qf8QQJaImb
💉Comparing #tusamitamab ravtansine vs #docetaxel
🦠metastatic nonsquamous #NSCLC
🔬 >50% of tumor expresses #CEACAM5 at 2+ intensity
🦀disease has progressed after prior therapy https://t.co/rkROTJTSWQ

1

2

0

196

@onc_ce

over 3 years ago

15b) Answer C! #Tusamitamab_ravtansine is an antibody-drug conjugate #ADC. It is the 🥇in class #CEACAM5-targeted agent. See J Clin Oncol. 2020;38[15 suppl]:9505 ⚗️this ADC = humanized antibody targeting CEACAM5 🤝cytotoxic maytansinoid derivative DM4

onc_ce's tweet photo. 15b) Answer C! #Tusamitamab_ravtansine is an antibody-drug conjugate #ADC. It is the 🥇in class #CEACAM5-targeted agent.
See J Clin Oncol. 2020;38[15 suppl]:9505

⚗️this ADC = humanized antibody targeting CEACAM5 🤝cytotoxic maytansinoid derivative DM4 https://t.co/9vvm9ny4OD

1

2

0

215

@onc_ce

over 3 years ago

15a) Which of the following is the compound targeting #CEACAM5? 🧪 A.Trastuzumab deruxtecan B.Amivantamab C.Tusamitamab ravtansine D.Patritumab deruxtecan

1

2

1

0

262

Top Tweets for #CEACAM5

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users